VBIO

Valion Bio Inc

1.21

Oct 20 • 2:16 PM ET +0.05 (4.32%)

Healthcare Biotechnology USA Nano NASD

Peers: LABT OGEN ARTL AZTR ADIL BBLG ABVC COAG TRAX AARD

Index	-
Market Cap	2.61M
Enterprise Value	25.55M
Income	-7.51M
Sales	0.48M
Book/sh	25.57
Cash/sh	0.98
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	52
IPO	Nov 11, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	5.43
P/B	0.05
P/C	1.24
P/FCF	-
EV/EBITDA	-
EV/Sales	53.22
Quick Ratio	0.86
Current Ratio	1.11
Debt/Eq	1.47
LT Debt/Eq	1.42
Option/Short	No / Yes

EPS (ttm)	-233.18
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	83.77% 59.16%
Sales past 3/5Y	- -
EPS Y/Y TTM	82.22%
Sales Y/Y TTM	-49.63%
EPS Q/Q	16.56%
Sales Q/Q	-100.00%
Earnings	May 14 AMC
EPS/Sales Surpr.	- -

Insider Own	0.29%
Insider Trans	176.83%
Inst Own	5.45%
Inst Trans	14.69%
ROA	-156.00%
ROE	-178.18%
ROIC	-26.10%
Gross Margin	-58.51%
Oper. Margin	-1548.96%
Profit Margin	-1557.26%
SMA20	-44.39%
SMA50	-57.49%
SMA200	-92.63%
Trades

Shs Outstand	1.95M
Shs Float	1.94M
Short Float	4.53%
Short Ratio	0.05
Short Interest	0.09M
52W High	74.50 -98.38%
52W Low	1.04 15.80%
Volatility	13.34% 21.39%
ATR (14)	0.47
RSI (14)	27.76
Beta	1.82
Rel Volume	0.04
Avg Volume	1.67M
Volume	51,437

Perf Week	-21.93%
Perf Month	-49.16%
Perf Quarter	-83.02%
Perf Half Y	-95.83%
Perf YTD	-96.66%
Perf Year	-98.30%
Perf 3Y	-99.77%
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	1.16
Price	1.21
Change %	4.32%

Oct-15-26 08:00AM	Valion Bio's Next-Generation NMR Partnership with LarmorBio Delivers Initial Feasibility Milestone (ACCESSWIRE) -15.17%
Oct-14-26 08:15AM	With Section 232 Tariffs Reshaping Biotech, Valion Bio's Velocity Bioworks Capitalizes on Domestic CDMO Surge (ACCESSWIRE) -6.45%
Oct-09-26 07:45AM	Valion Bio (Nasdaq:VBIO): Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiation Preparedness Should Nuclear Infrastructure Expand to Support Data Centers (ACCESSWIRE)
Oct-05-26 08:30AM	New Valion Bio Board Chair Thomas Jensen Brings Biotech Turnaround Experience to the Advancement of Entolimod (ACCESSWIRE)
Sep-30-26 10:41AM	Valion Bio Completes Oral Mucosal Entolimod Formulation, Opening Potential Needle-Free Development Pathway (InvestorsHub)
07:45AM	Loading…
07:45AM	Valion Bio and Shear Kershman Laboratories Successfully Formulate Oral Mucosal Entolimod; Valion Sees Potential for Multi-Fold Expansion of Long-Term Opportunity (ACCESSWIRE)
Sep-23-26 08:00AM	Valion Appoints Life Sciences Veteran Dean Zikria as Interim CEO and Announces Board Leadership Transitions (ACCESSWIRE) +9.64%
Sep-22-26 08:00AM	Valion Bio Regains Compliance with NASDAQ Minimum Bid Price Listing Rule (ACCESSWIRE)
Sep-01-26 08:00AM	Valion Bio Announces Changes to Management and Board of Directors (ACCESSWIRE) -14.01%
Aug-27-26 08:30AM	Valion Bio Announces Reverse Stock Split (ACCESSWIRE) -21.41%
Aug-13-26 10:00AM	Ukraine's Ministry Of Health Advances Entolimod Review Into Technical Assessment Phase (ACCESSWIRE) -24.42%
Aug-12-26 10:17AM	Valion Bio Advances Government-Funded Entolimod Radiation Injury Studies With Data Expected in Early Fall (InvestorsHub) -27.10%
09:29AM	Valion Bio Announces U.S. Government-Funded Entolimod Studies Targeting Lethal Radiation-Induced GI Injury (ACCESSWIRE)
Jul-22-26 07:45AM	Ukraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway (PR Newswire) -8.36%
Jul-20-26 01:28PM	World-Premier Cancer Center Sheba Medical Center Selects Entolimod for Clinical Trial, Potentially Expanding Valion Bio into the Multi-Billion-Dollar Neutropenia Market (PR Newswire) -28.50%
07:45AM	Loading…
Jul-14-26 07:45AM	Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion (PR Newswire) -7.64%
Jun-25-26 07:45AM	AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS (PR Newswire) +6.93%
Jun-11-26 07:45AM	Valion Bio (NASDAQ: VBIO) Confirms U.S. House Armed Services Committee Initiative to Address Urgent Need for Radiation /Nuclear Countermeasures (PR Newswire) -24.75%
May-19-26 04:38PM	VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME (PR Newswire) -5.57% +7.82%
May-14-26 04:31PM	Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR Platform (PR Newswire) -5.47%
04:05PM	VALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS (PR Newswire)
May-11-26 08:01AM	Valion Bio to Report First Quarter 2026 Financial Results on May 14, 2026 (PR Newswire) +15.62%
May-06-26 08:08AM	Valion Bio Celebrates Grand Opening of Velocity Bioworks Biomanufacturing Facility in San Antonio, Anchoring Domestic Production of Entolimod (PR Newswire)
May-05-26 08:00AM	VALION BIO RECEIVES FIRST FDA-PRECEDENT STUDY PROTOCOL FROM NIAID FOR ENTOLIMOD; FEDERAL AGENCY TO FULLY FUND BLA-ENABLING IN VIVO PROGRAM AND CO-NAVIGATE FDA SUBMISSION (PR Newswire)
May-04-26 04:05PM	Valion Bio Appoints Melinda Lackey as General Counsel (PR Newswire) +13.59%
Apr-28-26 08:01AM	VALION BIO BRIEFS PENTAGON LEADERSHIP ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME (PR Newswire) -27.86%
Apr-23-26 04:05PM	Tivic Health Systems Rebrands as Valion Bio, Reflecting Completed Transformation into a Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple Revenue Stream Model (PR Newswire) +18.75%
Apr-15-26 08:00AM	Tivic Health Selected to Present Entolimod as a Radiation Countermeasure and its Plans for an Oral Transmucosal Program to the Department of War Tech Watch Program on May 7th (PR Newswire) +12.90%
Mar-31-26 08:30AM	Tivic Receives Formal Request for Information from Ukrainian Ministry of Health Regarding Strategic Stockpiling of Entolimod (ACCESSWIRE)
Mar-27-26 11:30AM	Tivic CEO To Present at the Upcoming Emerging Growth's April 2026 Virtual Conference (ACCESSWIRE) -5.97%
08:30AM	Loading…
Mar-26-26 08:30AM	Tivic Secures NIAID Non-Clinical Evaluation Agreement for Entolimod, Targeting Gastrointestinal Acute Radiation Syndrome (ACCESSWIRE) -13.26%
Mar-25-26 04:05PM	Tivic Reports Full Year 2025 Results (ACCESSWIRE) +11.76%
Mar-24-26 09:30AM	Tivic Health CEO Letter to Shareholders (ACCESSWIRE)
Mar-20-26 03:35PM	Tivic To Report 2025 Year-End Financial Results Via Conference Call and Webcast on March 25th at 1:30pm PT / 4:30pm ET (ACCESSWIRE)
Mar-04-26 08:30AM	Biotech Veteran Michael K. Handley Named CEO of Tivic Health Systems to Spearhead Strategic Expansion in Biopharma (ACCESSWIRE) +5.02%
Feb-18-26 09:15AM	Tivic and BARDA Continue Discussions of Entolimod for Acute Radiation Syndrome on March 10 (ACCESSWIRE)
Jan-28-26 08:30AM	Tivic, BARDA Discuss Entolimod(TM) for Acute Radiation Syndrome at TechWatch Meeting (ACCESSWIRE)
Jan-26-26 10:10AM	Tivic to Showcase Strategic Pivot and Forward Outlook on Advancing Entolimod(TM) to Commercialization at DealFlow Discovery Conference (ACCESSWIRE)
Jan-20-26 05:50PM	Tivic CEO To Present at the Upcoming Emerging Growth's January 2026 Virtual Conference (ACCESSWIRE)
Jan-12-26 09:00AM	Tivic Delivers 200x Scale-up in Manufacturing for Lead Drug Candidate Entolimod(TM) And Achieves Reproducible Yields, Potency and Purity (ACCESSWIRE)
Jan-08-26 08:30AM	Tivic Announces Special Webcast To Discuss Its Recent Acquisition of CDMO Assets - Highlighting Near-Term Strategic Potential and Immediate Contributions to Accelerated Drug Development Timelines (ACCESSWIRE) +5.97%
Dec-11-25 09:45AM	Tivic Acquires Ready-to-Scale cGMP Manufacturing and Development Assets to Accelerate Commercialization of Entolimod; Tivic Growth Backed By $90M+ Financing Package (ACCESSWIRE) +11.76%
Nov-18-25 08:30AM	Tivic Secures Barda Meeting for Entolimod(TM) for Acute Radiation Syndrome (ACCESSWIRE) +25.08%
Nov-14-25 04:30PM	Tivic Reports Third Quarter 2025 Financial Results (ACCESSWIRE) -8.17% -21.31%
Nov-13-25 08:30AM	Tivic Health Reports Findings of Clinical Optimization Trial of Non-Invasive Cervical Vagus Nerve Stimulation (ncVNS) (ACCESSWIRE) -7.14%
Nov-10-25 09:00AM	Tivic Expands Intellectual Property Portfolio (Business Wire)
Nov-06-25 09:30AM	Tivic Health to Report Third Quarter 2025 Financial Results on November 14th Via Conference Call and Webcast (Business Wire) -9.68%
Oct-22-25 02:00PM	Tivic CEO, Jennifer Ernst, to Join Panel at 8th Annual Northwell Health Innovation Constellation Forum on Thursday, Oct. 23 (Business Wire)
Sep-22-25 08:30AM	Tivic Health CEO Jennifer Ernst to Present at Emerging Growth's September Virtual Conference (Business Wire)
Sep-10-25 08:30AM	Tivic Completes Verification of Entolimod Cell Line: First Step in Establishing CGMP Manufacturing for BLA Filing (Business Wire)
Aug-15-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +8.29%
08:30AM	Tivic Health Advances Discussions on Use of Entolimod as a Radiation Countermeasure at Military Health System Research Symposium 2025 (Business Wire)
Aug-14-25 04:00PM	Tivic Reports Second Quarter 2025 Financial Results (Business Wire)
Aug-07-25 08:30AM	Tivic Health to Report Second Quarter 2025 Financial Results on August 14th Via Conference Call and Webcast (Business Wire) -5.36%
Jul-08-25 08:30AM	Tivic Shareholders Approve Key Proposals in Support of Strategic Transformation; Lisa Wolf Appointed Permanent CFO (Business Wire)
Jun-25-25 08:30AM	Tivic Health Completes Optimization Study for Its Non-Invasive Vagus Nerve Stimulation Device (Business Wire)
Jun-24-25 08:30AM	Tivic Health Announces 2025 Annual Meeting of Stockholders (Business Wire)
Jun-13-25 08:35AM	Life Sciences Investor Forum: Now Available for Online Viewing (GlobeNewswire)
Jun-10-25 02:38PM	Life Sciences Investor Forum Agenda Announced for June 11th-12th (GlobeNewswire)
May-20-25 08:00AM	Sidoti Events, LLC's Virtual May Micro-Cap Conference (ACCESSWIRE)
May-15-25 04:05PM	Tivic Reports First Quarter 2025 Financial Results and Provides Updates on Business Transformation (Business Wire)
May-14-25 08:30AM	Tivic Health Enters GMP Manufacturing Validation Agreement with Scorpius BioManufacturing in Preparation for FDA Submission (Business Wire) +7.73%
May-13-25 08:30AM	Tivic Expands VNS Intellectual Property Portfolio (Business Wire) -5.20%
May-09-25 08:30AM	Tivic Health to Report First Quarter 2025 Financial Results on May 15th Via Conference Call and Webcast (Business Wire) -5.06%
Apr-22-25 08:30AM	Tivic Health Reports White House Briefing and FDA Meetings Secured Positive Interest in Potential Military and Defense Applications of Its Product Candidates (Business Wire) +103.71%
Apr-15-25 08:30AM	Tivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia (Business Wire) -10.96%
Apr-10-25 08:30AM	Tivic Health Systems, Inc. Regains Compliance with NASDAQ Minimum Bid Price Listing Rule (Business Wire) -7.68%
Mar-21-25 06:32PM	Tivic Health Systems, Inc. (TIVC) Q4 2024 Earnings Call Transcript (SeekingAlpha)
04:00PM	Tivic Reports Year End 2024 Financial Results and Provides Overview of Strategy for Transformation and Growth (Business Wire)
Mar-13-25 04:59PM	Tivic Health to Report 2024 Year-End Financial Results on March 21st Via Conference Call and Webcast (Business Wire) -6.74%
Mar-06-25 08:15AM	Tivic Health and Feinstein Institute Present New Data Showing Personalized Vagus Nerve Stimulation Method Optimizes Impact on Autonomic Nervous System (Business Wire) -12.67%
Mar-05-25 08:15AM	Tivic Health Systems, Inc. Announces Reverse Stock Split (Business Wire) -13.83%
Mar-03-25 08:15AM	Tivic Health Files Patent For Optimized Electrical Stimulation of the Vagus Nerve (Business Wire) -10.86%
Feb-24-25 08:15AM	Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team (Business Wire) -7.49%
Feb-12-25 08:30AM	Tivic Health Acquires Exclusive Worldwide Rights to Phase III TLR5 Agonist from Statera Biopharma (Business Wire) +197.87%
Dec-23-24 04:54PM	CEO Letter to Shareholders Issued by Tivic Health (Business Wire) +64.84%
Nov-15-24 11:46AM	Tivic hits enrolment target for vagus nerve stimulation trial (Medical Device Network) -21.08%
Nov-14-24 11:36PM	Tivic Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire) +10.91%
08:45AM	Enrollment Complete in Tivic Health Optimization Study for its Non-Invasive Vagus Nerve Stimulation Device (Business Wire)
Nov-12-24 08:30AM	Tivic Health Validates European Patents in Great Britain, Germany, and France (Business Wire)
Nov-07-24 08:30AM	Tivic Health Systems, Inc. to Report Third Quarter 2024 Financial Results on November 14 (Business Wire)
Oct-29-24 08:00AM	First Subject Enrolled in Tivic Healths Optimization Study for its Non-Invasive Vagus Nerve Stimulation Device (Business Wire)
Oct-24-24 08:30AM	Tivic Health CEO Jennifer Ernst to Present at New York BioFuture 2024 (Business Wire)
Sep-18-24 09:00AM	Tivic Health Receives Approval from Institutional Review Board for ncVNS Optimization Study, Readies for Enrollment (Business Wire)
Sep-17-24 09:00AM	Tivic Health Accelerates VNS Commercial Strategy Development (Business Wire)
Sep-13-24 05:29PM	Tivic Health Appoints Lisa Wolf as Interim Chief Financial Officer (Business Wire)
Aug-14-24 04:15PM	Tivic Reports Second Quarter 2024 Financial Results (Business Wire) -5.60% -7.05%
Aug-06-24 09:15AM	Tivic Health to Report Q2 2024 Financial Results and Corporate Update on August 14th Via Conference Call and Webcast (Business Wire) -15.19%
Aug-02-24 09:15AM	Tivic Announces 2024 Annual Meeting of Stockholders (Business Wire) -22.68%
Jul-29-24 11:58AM	Tivic Health Systems (TIVC) Stock Pops Another 39% (InvestorPlace) +55.31%
Jul-23-24 10:00AM	Tivic Health Expands Intellectual Property Portfolio (Business Wire) -11.00%
Jun-18-24 09:15AM	Tivic Health: Christina Valauri Appointed to Board of Directors (Business Wire)
May-22-24 09:00AM	Tivic Health Partners with the Feinstein Institutes to Advance its Patent-pending, Non-Invasive Cervical Vagus Nerve Stimulation; Begins Optimization of ncVNS for use in Clinical Indications (Business Wire)
May-15-24 08:52PM	TIVC Stock Earnings: Tivic Health Systems Reported Results for Q1 2024 (InvestorPlace)
04:26PM	Tivic Reports First Quarter 2024 Financial Results and Subsequent Events (Business Wire)
May-13-24 05:11PM	Tivic Health to Report Q1 2024 Financial Results and Subsequent Events on May 15th Via Conference Call and Webcast (Business Wire)
04:30PM	Tivic Health Announces Closing of $4.0 Million Public Offering (Business Wire)
May-09-24 09:20AM	Tivic Health Announces Pricing of $4.0 Million Public Offering (Business Wire) -55.97%
07:29AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
May-08-24 09:00AM	Tivic Health Announces Successful Completion of Non-Invasive Vagus Nerve Stimulation Study (VNS); Demonstrates Clinically Effective Biological Changes in the Autonomic, Cardiac, and Central Nervous Systems (Business Wire) +27.62%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bolton Sheryle	Director	Apr 15 '26	Buy	1.04	10,000	10,400	10,000	Apr 20 04:02 PM
Valauri Christina Rizopoulos	Director	Apr 01 '26	Buy	0.95	19,000	18,008	19,000	Apr 02 09:49 AM

Valion Bio, Inc. operates as a bio-electronic health-tech company, which develops micro current therapy solutions for chronic diseases and conditions. The company was founded by Jennifer Ernst and John Claude on September 22, 2016 and is headquartered in San Antonio, TX.

Interim CEO & DirectorMr. J. Dean Zikria

PresidentMs. Lisa G. Wolf

General Counsel & Senior Vice President of Legal AffairsMs. Melinda Lackey

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VBIO

Valion Bio Inc

Upgrade your Finviz experience